17th Feb 2021 11:15
Evgen Pharma PLC - Liverpool-based clinical stage drug development company - Says Star trial of SFX-01 recruits 102 patients as of Tuesday. The drug is used to treat acute respiratory infections. Recruitment will be completed at the end of 2021 or beginning of 2022.
Current stock price: 9.65 pence
Year-to-date change: down 5.4%
By Eric Cunha; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
EVG.L